CDCES Pathophysiology of Diabetes 2 — Questions and Answers
Question 1: What is the primary metabolic consequence of insulin deficiency in the liver?
- Decreased gluconeogenesis and glycogenolysis
- Unchecked gluconeogenesis and glycogenolysis leading to fasting hyperglycemia (Correct answer)
- Increased glycogen synthesis from dietary glucose
- Reduced fatty acid oxidation and ketogenesis
Correct answer: Unchecked gluconeogenesis and glycogenolysis leading to fasting hyperglycemia
Insulin normally suppresses hepatic glucose production; without insulin, gluconeogenesis and glycogenolysis are unchecked, contributing to fasting hyperglycemia.
Insulin's primary hepatic action is to suppress gluconeogenesis (new glucose synthesis from amino acids, lactate, glycerol) and glycogenolysis (glycogen breakdown to glucose). In insulin-deficient states, hepatic glucose production becomes unrestrained. Glucagon further stimulates glucose output. This accounts for the fasting hyperglycemia characteristic of both type 1 and type 2 diabetes. Metformin's primary mechanism of action targets this pathway by inhibiting hepatic gluconeogenesis. The CDCES explains why fasting glucose is often higher than expected even without carbohydrate intake.
Question 2: Which describes the mechanism by which SGLT2 inhibitors lower blood glucose?
- They stimulate pancreatic beta cells to produce more insulin
- They block SGLT2 transporters in the proximal tubule, preventing renal glucose reabsorption (Correct answer)
- They increase GLP-1 secretion from intestinal L-cells
- They inhibit hepatic gluconeogenesis through AMPK activation
Correct answer: They block SGLT2 transporters in the proximal tubule, preventing renal glucose reabsorption
SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney's proximal tubule, causing glucosuria (urinary glucose excretion) and lowering blood glucose without insulin stimulation.
SGLT2 (sodium-glucose cotransporter 2) is responsible for reabsorbing approximately 90% of filtered glucose in the renal proximal tubule. SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin) block this transporter, causing 60-100g of glucose to be excreted in urine daily -- an insulin-independent mechanism. This results in mild glucose lowering, weight loss (caloric loss), blood pressure reduction, and cardiovascular/renal benefits independent of glucose lowering. The CDCES teaches patients about glucosuria as an expected drug effect and the risk of genital mycotic infections and euDKA.
Question 3: Maturity-onset diabetes of the young (MODY) is most commonly caused by which mechanism?
- Autoimmune destruction of beta cells triggered by viral infection
- Single-gene mutations affecting beta-cell function or glucose sensing (Correct answer)
- Accelerated insulin resistance due to genetic obesity genes
- Mitochondrial DNA mutations reducing cellular energy production
Correct answer: Single-gene mutations affecting beta-cell function or glucose sensing
MODY is a monogenic diabetes caused by single-gene mutations (most commonly in GCK, HNF1A, or HNF4A genes) that impair beta-cell function or glucose sensing.
MODY (maturity-onset diabetes of the young) comprises at least 14 genetic subtypes caused by single-gene (monogenic) mutations affecting beta-cell development or function. The most common types are: MODY2 (GCK gene -- glucokinase mutation, mild stable hyperglycemia, often diet-managed), MODY3 (HNF1A -- sulfonylurea-responsive), and MODY1 (HNF4A). MODY is typically inherited in an autosomal dominant pattern and presents before age 25 in non-obese individuals with family history of diabetes. Genetic testing confirms diagnosis. Correctly identifying MODY changes treatment (sulfonylurea for MODY3 vs. insulin for presumed T1D).
Question 4: What is the role of amylin in glucose regulation, and how does its deficiency affect diabetes management?
- Amylin stimulates glucagon secretion; its deficiency worsens postprandial hypoglycemia
- Amylin suppresses glucagon, slows gastric emptying, and promotes satiety; its deficiency contributes to postprandial hyperglycemia in type 1 diabetes (Correct answer)
- Amylin promotes insulin release from beta cells; its deficiency reduces basal insulin
- Amylin has no clinically significant role in glucose metabolism
Correct answer: Amylin suppresses glucagon, slows gastric emptying, and promotes satiety; its deficiency contributes to postprandial hyperglycemia in type 1 diabetes
Amylin (co-secreted with insulin from beta cells) suppresses glucagon, slows gastric emptying, and promotes satiety; in T1D with beta-cell loss, amylin deficiency contributes to postprandial glucose excursions.
Amylin (islet amyloid polypeptide, IAPP) is secreted alongside insulin by pancreatic beta cells in a fixed molar ratio. Its three primary actions: (1) suppress postprandial glucagon secretion, (2) slow gastric emptying, (3) promote CNS satiety signals. In type 1 diabetes (complete beta-cell destruction), amylin is completely absent, contributing to inappropriate postprandial glucagon rise and rapid glucose absorption. Pramlintide (Symlin) is a synthetic amylin analog approved for T1D and insulin-using T2D patients to address these deficiencies. The CDCES educates patients on pramlintide use and the need to reduce prandial insulin doses.
Question 5: Which physiological mechanism explains why patients with longstanding type 1 diabetes may lose the early warning symptoms of hypoglycemia?
- Hypoglycemia unawareness occurs because insulin antibodies blunt glucose fluctuations
- Repeated hypoglycemia episodes downregulate counter-regulatory hormone responses and shift the glycemic threshold for symptom generation (Correct answer)
- The autonomic neuropathy of diabetes destroys all pancreatic glucagon cells permanently
- Long-term CGM use reduces the brain's ability to perceive glucose changes
Correct answer: Repeated hypoglycemia episodes downregulate counter-regulatory hormone responses and shift the glycemic threshold for symptom generation
Hypoglycemia unawareness results from recurrent hypoglycemia that downregulates epinephrine and glucagon counter-regulatory responses and lowers the BG threshold at which symptoms appear.
Hypoglycemia-associated autonomic failure (HAAF) is a syndrome in which prior hypoglycemia episodes blunt the counter-regulatory response to subsequent hypoglycemia. Specifically, repeated low BG reduces epinephrine secretion and glucagon responses, and shifts the glycemic threshold at which adrenergic symptoms (shakiness, sweating, palpitations) occur to progressively lower BG levels. Patients may not experience warning symptoms until BG drops to dangerously low levels. Treatment includes hypoglycemia avoidance (strict avoidance of low BG for 2-3 weeks can partially restore awareness) and use of CGM with low-glucose alerts.
Question 6: Hepatic steatosis (fatty liver) is most commonly associated with which form of diabetes?
- Type 1 diabetes due to insulin deficiency
- Type 2 diabetes and insulin resistance, especially with obesity (Correct answer)
- Gestational diabetes due to placental lipid transfer
- MODY due to HNF1A mutation affecting lipid metabolism
Correct answer: Type 2 diabetes and insulin resistance, especially with obesity
Non-alcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes and insulin resistance, particularly in the setting of visceral obesity.
NAFLD/MAFLD (metabolic-associated fatty liver disease) is present in approximately 55-70% of patients with type 2 diabetes and is driven by insulin resistance, which impairs suppression of adipose lipolysis and hepatic de novo lipogenesis. Ectopic fat deposition in the liver worsens hepatic insulin resistance, creating a vicious cycle. NAFLD can progress to NASH (non-alcoholic steatohepatitis), cirrhosis, and hepatocellular carcinoma. GLP-1 receptor agonists, pioglitazone, and SGLT2 inhibitors have evidence for benefit in NAFLD. The CDCES includes liver health education in comprehensive diabetes management counseling.
CDCES Pathophysiology of Diabetes 2
What is the primary metabolic consequence of insulin deficiency in the liver?